In December 2023, the professional team from VCRO assisted the client in submitting the clinical trial application of their viral vector for the use of gene therapy in the treatment of retinal diseases. The team successfully obtained US FDA approval to proceed with Phase I/II clinical trials. We successfully supported our clients in smoothly advancing to the Phase I/II clinical trial stage. VCRO is here to accompany you through every stage of the clinical trial process.